Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03843125 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,147
- Enrollment target
NCT03843125 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,147 participants.
The verdict
NCT03843125, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,147 participants
- Enrollment target
Study Summary
The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).
Interventions
- DRUG Placebo
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,147 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2022-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03843125
The ClinicalTrials.gov registry entry for NCT03843125 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03843125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03843125 about?
NCT03843125 is a clinical study titled "A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)". The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).
What is the current status of trial NCT03843125?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,147 participants. The study started on 2019-09-09. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT03843125?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT03843125?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.